According to a series of study results being published in a special issue of Diabetes Care youth with type 2 diabetes experience a more rapid progression of co-morbidities far more aggressive than what is typically seen in adults, even when they receive the best currently available treatment and close monitoring of their condition.
Dr. Harrison and his team identified that some T cells express a molecule on their surfaces, CD52, that is capable of suppressing other T cells. Understanding the ways in which the immune system normally controls and suppresses T cells is crucial to our understanding what goes wrong in autoimmune diseases.
The U.S. FDA has announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay), manufactured by Roche, for the diagnosis of diabetes by health care professionals. This is the first HbA1c test that FDA has allowed to be marketed for this use.
Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).
I was diagnosed with type 1 diabetes seventeen years ago. That’s the amount of time it takes to raise a child. With all the TLC I’ve provided, Diabetes…
The biomaterial holding the islet cells—which is completely synthetic, is 96 percent water, and which Garcia described as having the consistency of diluted Jello-O—and that was infused into the mice, however, addresses several of these problems.